Valuation: Sera Prognostics, Inc.

Market Cap 84.42M 72.32M 67.66M 61.94M 116M 8.08B 118M 799M 312M 4.06B 317M 310M 13.42B P/E 2026 *
-3.25x
P/E 2027 * -4x
Enterprise Value 84.42M 72.32M 67.66M 61.94M 116M 8.08B 118M 799M 312M 4.06B 317M 310M 13.42B EV / Sales 2026 *
375x
EV / Sales 2027 * 43.9x
Free-Float
85.92%
Yield 2026 *
-
Yield 2027 * -
1 day+1.90%
1 week+9.18%
Current month+4.90%
1 month-5.73%
3 months+18.89%
6 months-14.74%
Current year-27.46%
1 week 1.92
Extreme 1.915
2.16
1 month 1.85
Extreme 1.8514
2.25
Current year 1.56
Extreme 1.56
3.85
1 year 1.56
Extreme 1.56
3.95
3 years 1.37
Extreme 1.37
12.36
5 years 1.1
Extreme 1.1
12.36
10 years 1.1
Extreme 1.1
15.5
Manager TitleAgeSince
Chief Executive Officer 52 31/05/2023
Director of Finance/CFO 39 06/06/2023
Chief Tech/Sci/R&D Officer - 31/12/2021
Director TitleAgeSince
Chairman 74 19/04/2011
Chairman 58 07/06/2023
Director/Board Member 59 31/10/2011
Date Insider Type Main position Quantity % Market Cap.
10/07/26 Free

Director

62,657 0.1641%
10/07/26 Free

Director

62,697 0.1642%
10/07/26 Free

Director

61,416 0.1608%
Change 5-day change 1-year change 3-year change Capi.($)
+1.90%+9.18%-10.08%+4.90% 84.42M
-0.06%-1.99%+11.07%+15.39% 22.81B
-0.85%+8.23%+17.83%-23.43% 3.79B
+0.87%-1.65%+50.57%+47.45% 3.25B
-1.13%+1.45%-27.63%-33.52% 2.09B
+5.43%-3.45%-7.13% - 2.08B
-1.60%-1.71%-21.54%+12.54% 1.57B
+0.90%-6.01%+63.20%+101.20% 1.4B
+0.41%-0.99%-22.00%+5.89% 1.32B
+2.28%-7.51%+45.37%+134.96% 1.12B
Average +0.82%-3.29%+9.97%+29.49% 3.95B
Weighted average by Cap. +0.23%-2.92%+12.32%+17.81%

Financials

2026 *2027 *
Net sales 225K 193K 180K 165K 310K 21.53M 314K 2.13M 831K 10.81M 845K 826K 35.77M 1.92M 1.65M 1.54M 1.41M 2.65M 184M 2.69M 18.23M 7.11M 92.52M 7.23M 7.07M 306M
Net income -33.93M -29.07M -27.2M -24.9M -46.72M -3.25B -47.34M -321M -125M -1.63B -127M -125M -5.39B -29.1M -24.93M -23.32M -21.35M -40.07M -2.78B -40.6M -276M -107M -1.4B -109M -107M -4.63B
Net Debt - -
Logo Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Employees
72
Date Price Change Volume
21/08/26 US$2.140 +1.90% 14,573
20/08/26 US$2.100 +5.53% 30,863
19/08/26 US$1.990 +3.11% 26,262
18/08/26 US$1.930 -1.03% 9,492
17/08/26 US$1.950 -0.51% 26,943
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.140USD
Average target price
5.500USD
Spread / Average Target
+157.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SERA Stock